- Home
- MRAM vs VIGL Comparison
MRAM vs VIGL Comparison
Compare MRAM & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- VIGL
- Stock Information
- Founded
- MRAM 2008
- VIGL 2020
- Country
- MRAM United States
- VIGL United States
- Employees
- MRAM N/A
- VIGL N/A
- Industry
- MRAM Semiconductors
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- VIGL Health Care
- Exchange
- MRAM Nasdaq
- VIGL Nasdaq
- Market Cap
- MRAM 140.4M
- VIGL 95.2M
- IPO Year
- MRAM 2016
- VIGL 2022
- Fundamental
- Price
- MRAM $6.23
- VIGL $1.70
- Analyst Decision
- MRAM Strong Buy
- VIGL Buy
- Analyst Count
- MRAM 2
- VIGL 6
- Target Price
- MRAM $9.00
- VIGL $16.60
- AVG Volume (30 Days)
- MRAM 136.7K
- VIGL 387.1K
- Earning Date
- MRAM 10-30-2024
- VIGL 11-07-2024
- Dividend Yield
- MRAM N/A
- VIGL N/A
- EPS Growth
- MRAM N/A
- VIGL N/A
- EPS
- MRAM 0.07
- VIGL N/A
- Revenue
- MRAM $53,865,000.00
- VIGL N/A
- Revenue This Year
- MRAM N/A
- VIGL N/A
- Revenue Next Year
- MRAM $7.15
- VIGL N/A
- P/E Ratio
- MRAM $87.36
- VIGL N/A
- Revenue Growth
- MRAM N/A
- VIGL N/A
- 52 Week Low
- MRAM $4.89
- VIGL $1.60
- 52 Week High
- MRAM $9.43
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- MRAM 49.14
- VIGL 23.30
- Support Level
- MRAM $6.19
- VIGL $1.60
- Resistance Level
- MRAM $6.68
- VIGL $2.46
- Average True Range (ATR)
- MRAM 0.26
- VIGL 0.16
- MACD
- MRAM -0.01
- VIGL -0.02
- Stochastic Oscillator
- MRAM 29.22
- VIGL 11.63
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA); and Asia-Pacific (APAC).
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.